This study was funded by an internal institutional grant, and no third-party funding was received.
The authors declare that there were no conflicts of interest.
High-performance liquid chromatography
Interquartile (25th to 75th percentile) range
Teva, Gardena, Calif.
JT Baker Inc, Phillipsburg, NJ.
EMD Chemicals Inc, Port Wentworth, Ga.
Acumedia, Lansing, Mich.
Croda Healthcare, Edison, NJ.
Pharmaco, Brookfield, Conn.
Spectrum, Gardena, Calif.
MedTox Laboratories, Saint Paul, Minn.
Prism 8, GraphPad Software, San Diego, Calif.
RMCORR, version 0.4.1 (2017), R Core Team, R Foundation for Statistical Computing, Vienna, Austria.
- 1. ↑
Schober KE, Zientek J, Li X, et al. Effect of treatment with atenolol on 5-year survival in cats with preclinical (asymptomatic) hypertrophic cardiomyopathy. J Vet Cardiol 2013;15:93–104.
- 2. ↑
Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775–785.
- 3. ↑
Macgregor JM, Rush JE, Rozanski EA, et al. Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. Am J Vet Res 2008;69:39–44.
Khor KH, Campbell FE, Charles BG, et al. Comparative pharmacokinetics and pharmacodynamics of tablet, suspension and paste formulations of atenolol in cats. J Vet Pharmacol Ther 2012;35:437–445.
- 6. ↑
Rush JE, Freeman LM, Fenollosa NK, et al. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999). J Am Vet Med Assoc 2002;220:202–207.
- 7. ↑
Ahad A, Al-Jenoobi FI, Al-Mohizea AM, et al. Systemic delivery of β-blockers via transdermal route for hypertension. Saudi Pharm J 2015;23:587–602.
- 8. ↑
Mohamed SM, Christensen JM, LeBlanc NL. Transdermal formulation development and topical administration of atenolol to cats. Pharmacol Pharm 2020;11:39–53.
- 9. ↑
Riviere JE, Papich MG. Potential and problems of developing transdermal patches for veterinary applications. Adv Drug Deliv Rev 2001;50:175–203.
- 10. ↑
Frishman MH. Pharmacodynamic and pharmacokinetic properties. In: Clinical pharmacology of the beta-adrenoceptor blocking drugs. New York: Appleton-Century-Crofts, 1980;1–14.
- 11. ↑
Hoffman SB, Yoder AR, Trepanier LA. Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther 2002;25:189–193.
- 12. ↑
Jackson G, Schwartz J, Kates RE, et al. Atenolol: once-daily cardioselective beta blockade for angina pectoris. Circulation 1980;61:555–560.
- 13. ↑
Lin Y, Ma R, Wang B, et al. The degradation and persistence of five pharmaceuticals in an artificial climate incubator during a one year period. RSC Adv 2017;7:8280–8287.